Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Rich Pharmaceuticals taps I2R as CRO of choice
February 2018
SHARING OPTIONS:

BEVERLY HILLS, Calif.—Biopharmaceutical company Rich Pharmaceuticals Inc. has selected IND 2 Results LLC (I2R) as its contract research organization. I2R will attend to protocol development, medical writing and regulatory consulting for Rich Pharmaceuticals as the latter advances plans for clinical trials in Hodgkin’s lymphoma, and will also help the company prepare its protocol for submission to the FDA. I2R will aid Rich Pharmaceuticals in adjusting its protocol for acute myelocytic leukemia as well, in preparation for the submission package to a major U.S. clinical site, and see to submission packages for the site’s Institutional Review Board.
 
“I2R has a strong track record of success in conducting complicated clinical trials. Its multidisciplinary team of experienced clinical trial professionals will work with Rich Pharmaceuticals as we move forward with our innovative treatment for lymphoma and leukemia,” said Ben Chang, Rich Pharmaceuticals CEO. “We believe that getting a talented CRO team on board is an important step for our future.”

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2018 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.